(VIANEWS) – Bionano Genomics (NASDAQ: BNGO) shares have seen a remarkable 26% gain since December 15, with EUR1.5 trading at its 52-week low of EUR22.90 and rising up from there. Investors remain bullish despite broad market weakness; with the NASDAQ index falling 0.56% over 10 sessions to EUR15,011.35. BNGO investors remain bullish despite market fluctuations; it currently trades 91.75% below this mark.
About Bionano Genomics
Bionano Genomics, Inc. specializes in genome analysis software and solutions for genomics labs. Their flagship product, Saphyr, offers optical genome mapping-based structural variation analysis that provides insights into genetic variation and function. Additionally, Bionano Genomics also provides ultra-high molecular weight DNA analysis using Saphyr instruments with consumables/reagents/reagents provided with ultra-high molecular weight DNA as well as NxClinical software to analyze/interpret variants; additionally they offer testing/ laboratory services for autism spectrum disorder/ Fragile X syndrome/epilepsy diagnosis/interpretations services/ tests/analyses/interpretations services/. Established in 2003, Bionano Genomics has headquarters located in San Diego California since 2003 and currently operates out of San Diego California
Yearly Analysis
Based on available data, Bionano Genomics stock is trading at EUR1.89 per share; significantly below its 52-week high of EUR22.90 but higher than its 52-week low of EUR1.19. This indicates a period of fluctuation during 2017, yet investors could remain hopeful in its performance given projected sales increases for this and next year.
According to data provided, Bionano Genomics’ sales growth is projected at 29.3 % this year and 43.3 % for next year – this signals an anticipated revenue surge over time that can only bode well for investors.
Bionano Genomics currently boasts an EBITDA figure of 0.33, which suggests that they are making a modest profit after accounting for interest, taxes, depreciation and amortization expenses. Unfortunately, without additional information regarding expenses it is hard to know whether this EBITDA figure reflects an optimistic financial position or not.
Overall, investors should evaluate Bionano Genomics stock with regards to anticipated sales growth and financial performance. It should also be kept in mind that investing is inherently uncertain; past performance does not guarantee future outcomes.
Technical Analysis
Bionano Genomics (BNG), a biotechnology company specializing in genome analysis, has seen its stock prices significantly decline. Their current stock value falls far below their 50-day moving average of EUR1.91 and far short of their 200-day moving average of EUR6.02.
Even as stock values decline, trading volume remains unusually high. Today’s reported volume of 2,496,584 represents 80.01% more trading activity than its average volume of 1,386,880 and may indicate investor enthusiasm or unease over future performance of the company.
Over the last week, this stock has experienced an average daily volatility of 3.06% with the highest amplitude being 8.53 per cent. Month and quarter volatility averaged respectively at 6.25 and 5.73% respectively.
The stochastic oscillator, an indicator of overbought and oversold conditions, classifies Bionano Genomics stock as overbought (>=80) according to current market trends, suggesting it could soon experience price correction.
Based on these findings, investors may wish to closely follow Bionano Genomics’s stock performance and consider potential entry or exit points based on future financial reports and industry developments.
Quarter Analysis
Sales Growth @ Nano GenomicsBoth this quarter and in the following one have seen unprecedented sales increases of 28.3% and 46.5%, respectively. Growth Estimates Quarters The company’s current and next quarter growth estimates stand at 33.1% and 37.5%, respectively. These estimates indicate that Bionano Genomics should continue on its upward path. Revenue GrowthBionano Genomics reported a 29% year-on-year revenue growth for its most recent quarterly period; with total twelve-month trailing revenue reaching 33.61M. Bionano Genomics has shown its ability to generate steady revenue growth over time, which bodes well for investors. Based on strong sales growth, growth estimates, and revenue projections, its investment outlook seems positive; investors might consider adding it to their portfolio if looking for biotechnology stocks with strong growth potential.
Equity Analysis
Bionano Genomics currently boasts an EPS of EUR-7.17 for its trailing twelve month period ending September 2015, reflecting negative earnings and no current profit for shareholders.
Furthermore, the company’s return on equity (ROE) for the twelve trailing months stands at -113.43% – this indicates that profits are not being generated efficiently or that shareholder equity is being utilized efficiently by management.
Overall, these financial metrics suggest that Bionano Genomics is currently underperforming in terms of profitability. Investors should carefully consider this information when making investment decisions.
More news about Bionano Genomics (BNGO).
